Koselugo, which is a treatment for pediatric patients with neurofibromatosis, has entered its last gateway to receiving reimbursement in Korea.

According to industry sources, AstraZeneca has recently started drug pricing negotiations with the National Health Insurance Service to set the insurance price for its new neurofibromatosis drug, Koselugo.

Whether Koselugo, which passed the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee review on the 7th of last month after 3 attempts, will be able to settle on a final drug price during negotiations and be listed for reimbursement remains to be seen.

This drug has remained non-reimbursed